Start Codon launched in Cambridge, England with funding from keystone investors including Cambridge Innovation Capital, Babraham Bioscience Technologies, Genentech, Jonathan Milner and Ian Tomlinson.

Donating billions of dollars to global funds that fight poverty and disease is one of the best investments governments can make to boost security and economic growth, philanthropists Bill and Melinda Gates said.

Nestle’s health science arm will pay $98 million to raise its stake in Aimmune Therapeutics in preparation of submitting a marketing application for the peanut allergy drug AR101 by year-end 2018.

To spur innovation and bolster ties with tech giants, Swiss pharma giant Novartis plans to set up innovation labs across the globe to partner with these companies to spur the development of new therapies.

GO Therapeutics, with headquarters in Cambridge, Mass., signed a licensing deal with Swiss-based Roche to develop antibodies for cancer.

In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding.

Pfizer Inc. announced plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture investment vehicle.

Roche Holding will buy the rest of U.S. cancer data company Flatiron Health that the Swiss drugmaker does not already own for $1.9 billion to speed development of cancer medicines.

Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.

Pershing Square, a hedge fund run by activist investor William Ackman, and Valeant decided to settle an insider trading lawsuit with Allergan and pay $290 million.